Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Matucci

Showing results (251-260 of 295) with videos related to

Pageof 30
Sort By:
Diagnostic Cytopathology|June 27, 2003
Clinical impact (cost-effectiveness) of qualifying atypical squamous cells of undeterminate significance (ASCUS) in cases favoring a reactive or dysplastic processF M Carozzi, M P Cariaggi, L Bonardi, et al.
Respiration; International Review of Thoracic Diseases|October 22, 2008
Induced sputum in systemic sclerosis interstitial lung disease: comparison to healthy controls and bronchoalveolar lavageN Damjanov, P Ostojic, O Kaloudi, et al.
Arthritis and Rheumatism|August 18, 2001
Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosisO Kowal-Bielecka, O Distler, M Neidhart, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Rheumatology (Oxford, England)|August 29, 2006
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosisO Kaloudi, G Basta, F Perfetto, et al.
Annals of the Rheumatic Diseases|August 17, 2004
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committeesM Dougados, N Betteridge, G R Burmester, et al.
Clinical and Experimental Rheumatology|September 22, 2005
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn)F Bandinelli, F Bartoli, E Perfetto, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2018
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysisL Gragnani, G Cerretelli, S Lorini, et al.
Arthritis Care & Research|June 8, 2012
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational studyF Tubach, P Ravaud, E Martin-Mola, et al.
Pageof 30

Showing results (251-260 of 295) with videos related to

Sort By:
Pageof 30
Diagnostic Cytopathology|June 27, 2003
Clinical impact (cost-effectiveness) of qualifying atypical squamous cells of undeterminate significance (ASCUS) in cases favoring a reactive or dysplastic processF M Carozzi, M P Cariaggi, L Bonardi, et al.
Respiration; International Review of Thoracic Diseases|October 22, 2008
Induced sputum in systemic sclerosis interstitial lung disease: comparison to healthy controls and bronchoalveolar lavageN Damjanov, P Ostojic, O Kaloudi, et al.
Arthritis and Rheumatism|August 18, 2001
Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosisO Kowal-Bielecka, O Distler, M Neidhart, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Rheumatology (Oxford, England)|August 29, 2006
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosisO Kaloudi, G Basta, F Perfetto, et al.
Annals of the Rheumatic Diseases|August 17, 2004
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committeesM Dougados, N Betteridge, G R Burmester, et al.
Clinical and Experimental Rheumatology|September 22, 2005
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn)F Bandinelli, F Bartoli, E Perfetto, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2018
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysisL Gragnani, G Cerretelli, S Lorini, et al.
Arthritis Care & Research|June 8, 2012
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational studyF Tubach, P Ravaud, E Martin-Mola, et al.
Pageof 30